Uveitis: Mechanisms and recent advances in therapy

Clinica Chimica Acta

Volumn 411, Issue 17-18, 2010, Pages 1165-1171

  Srivastava, Arpna ^a   Rajappa, Medha ^a   Kaur, Jasbir ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokine; Gene therapy; Intraocular inflammation; Uveitis

Indexed keywords

ADENOVIRUS VECTOR; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LENTIVIRUS VECTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADENOVIRUS; ANTIINFLAMMATORY ACTIVITY; BEHCET DISEASE; CONJUNCTIVITIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EYE INFLAMMATION; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LENTIVIRINAE; LUPUS ERYTHEMATOSUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TREATMENT RESPONSE; UVEITIS; VIRAL GENE DELIVERY SYSTEM; IMMUNOLOGY;

GENE THERAPY; HUMANS; RNA INTERFERENCE; UVEITIS; GENETIC THERAPY;

ANIMALIA;

EID: 77954141742     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.04.017     Document Type: Review

References (71)

1. Nussenblatt R.B., Whitcup S.M., Palestine A.G. Uveitis: fundamentals and clinical practice 1996, Mosby Year Book, St. Louis. 2nd ed.
2. Rosenbaum J.T., Samples J.R., Hefeneider S.H., Howes E.L. Ocular inflammatory effects of intravitreal interleukin-1. Arch Ophthalmol 1987, 105:1117-1120.
3. Mo J.S., Matsukawa A., Ohkawara S., Yoshinaga M. Involvement of TNF-α, IL-1beta and IL-1 receptor antagonist in LPS induced rabbit uveitis. Exp Eye Res 1998, 66:547-557.
4. Bhattacherjee P., Henderson B. Inflammatory responses to intraocularly injected interleukin-1. Curr Eye Res 1987, 6:929-934.
5. Pennesi G., Mattapallil M.J., Sun S.H., Avichezer D., Silver P.B., Karabekian Z., et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest 2003, 111:1171-1180.
6. Smith J.R., Hart P.H., Williams K.A. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol 1998, 76:497-512.
7. Bodaghi B., Rao N. Relevance of animal models to human uveitis. Ophthalmic Res 2008, 40:200-202.
8. Kwashima H. Chemokine-their role in immunotherapy for intraocular inflammation. Ocul Immunol Inflamm 2003, 11:83-90.
9. Greiner K., Plskova J. TNF-α inhibitors in the treatment of uveitis. Ophthalmologe 2005, 102:335-340.
10. De Vos A.F., Klaren V.N., Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994, 35:3873-3883.
11. Okada A.A., Sakai J., Usui M., Mizuguchi J.J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998, 6:111-120.
12. Nakamura S., Yamakawa T., Sugita M., Kijima M., Ishioka M., Tanaka S., et al. The role of tumor necrosis factor-α in the induction of experimental uveoretinitis in mice. Invest Ophthalmol Vis Sci 1994, 35:3884-3889.
13. Dick A.D., Duncan L., Hale G., Waldmann H., Isaacs J. Neutralizing TNF-α activity modulates T-cell phenotype function in experimental autoimmune uveoretinitis. J Autoimmun 1998, 11:255-264.
14. Robertson M., Liversidge J., Forrester J.V., Andrew D.D. Neutralizing tumor necrosis factor-α activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003, 44:3034-3041.
15. + T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 2004, 45:170-176.
16. Santos Lacomba M., Marcos Martin C., Gallardo Galera J.M., Gomez Vidal M.A., Collantes Estevez E., Ramirez Chamond R. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 2001, 33:251-255.
17. Turan B., Gallati H., Erdi H., Gurler A., Michel B.A., Villiger P.M., et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997, 24:128-132.
18. Maini R., St Clair E.W., Breedveld F., Frust D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor-alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354:1932-1939.
19. Kavanaugh A., St Clair E.W., McCune W.J., Braakman T., Lipsky P. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000, 27:841-850.
20. Sandborn W.J., Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:119-133.
21. Serio R.N. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003, 37:577-581.
22. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
23. Ogilvie A.L., Antoni C., Dechant C., Manger B., Kalden J.R., Schuler G., et al. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001, 144:587-589.
24. Wollina U., Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 2002, 16:127-129.
25. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., Markomichelakis N.N. Effect of infliximab on sight threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296.
26. El-Shabrawi Y., Hermann J. Anti-tumor necrosis factor-α therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109:2342-2346.
27. Smith J.R., Levinson R.D., Holland G.N., Jabs D.A., Robinson M.R., Whitcup S.M., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45:252-257.
28. Reiff A., Takei S., Sadeghi S., Stout A., Shaham B., Branstein B., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415.
29. Sicotte N.L., Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
30. Ten Tusscher M.P., Jacobs P.J., Busch M.J., De Graaf L.L., Diemont W. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003, 326:579.
31. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Eng J Med 2001, 345:1098-1104.
32. Lee J.H., Slifman N.R., Gershon S.K., Edwards E.T., Schwieterman W.D., Seigel J.N., et al. Life-threatening histoplasmosis complicating immunotherapy with tumour necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
33. Lindstedt E.W., Baarma G.S., Kuijpers R.W.A., Hagen P.M. Anti-TNF-α therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533-536.
34. Caspi R.R. Immunotherapy of uveitis: is gene therapy in our future?. Uveitis and immunological disorders 2007, 193-210. Springer Berlin Heidelberg. U. Pleyer, C.S. Foster (Eds.).
35. Fang I.M., Lin C.P., Yang C.H., Chiang B.L., Yang C.M., Chan L.Y., et al. Inhibition of experimental autoimmune anterior uveitis by adenovirus-mediated transfer of the interleukin-10 gene. J Ocul Pharmacol Ther 2005, 21:420-428.
36. Trittibach P., Barker S.E., Broderick C.A., Natkunarajah M., Duran Y., Robbie S.J., et al. Lentiviral vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther 2008, 15:1478-1488.
37. Grool T.A., van Dullemen H., Meenan J., Koster F., ten Kate F.J., Lebeaut A., et al. Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis. Scand J Gastroenterol 1998, 33:754-758.
38. Apparailly F., Verwaerde C., Jacquet C., Auriault C., Sany J., Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998, 160:5213-5220.
39. Hayashi S., Guex-Crosier Y., Delvaux A., Velu T., Roberge F.G. Interleukin 10 inhibits inflammatory cells infiltration in endotoxin induced uveitis. Graefes Arch Clin Exp Ophthalmol 1996, 234:633-636.
40. Broderick C.A., Smith A.J., Balaggan K.S., Georgiadis A., Buch P.K., Trittibach P.C., et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol Ther 2005, 12:369-373.
41. De Kozak Y., Thillaye-Goldenberg B., Naud M.C., Da Costa A.V., Auriault C., Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus mediated transfer of the viral IL-10 gene. Clin Exp Immunol 2002, 130:212-223.
42. Arend W.P. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002, 13:323-340.
43. Makarov S.S., Olsen J.C., Johnston W.N., Anderle S.K., Brown R.R., Baldwin A.S., et al. Suppression of experimental arthritis by gene transfer of interleukin-1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996, 93:402-406.
44. Pan R.Y., Chen S.L., Xiao X., Liu D.W., Peng H.J., Tsao Y.P. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000, 43:289-297.
45. Huhn R.D., Radwanski E., O'Connell S.M., Sturgill M.G., Clarke L., Cody R.P., et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996, 87:699-705.
46. Gouze J.N., Gouze E., Palmer G.D., Liew V.S., Pascher A., Betz O.B., et al. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer. Arthritis Res Ther 2003, 5:R301-R309.
47. Smith J.R., Verwaerde C., Rolling F., Naud M.C., Delanoye A., Thillaye-Goldenberg B., et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther 2005, 16:1037-1046.
48. Tsai M.L., Horng C.T., Chen S.L., Xiao X., Wang C.H., Tsao Y.P. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis 2009, 1542-1552.
49. Keane-Myers A.M., Miyazaki D., Liu G., Dekaris I., Ono S., Dana M.R. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 1999, 40:3041-3046.
50. Dana M.R., Yamada J., Streilein J.W. Topical interleukin-1 receptor antagonist promotes corneal transplant survival. Transplantation 1997, 63:1501-1507.
51. Lim W.K., Fujimoto C., Ursea R., Mahesh S.P., Silver P., Chan C.C., et al. Suppression of immune-mediated ocular inflammation in mice by interleukin-1 receptor antagonist administration. Arch Ophthalmol 2005, 123:957-963.
52. Rosenbaum J.T., Boney R.S. Activity of an interleukin-1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol 1992, 110:547-549.
53. Pepose J.S., Leib D.A. Herpes simplex viral vectors for therapeutic gene delivery to ocular tissues. Recent breakthroughs in the molecular genetics of ocular diseases. Invest Ophthalmol Vis Sci 1994, 35:2662-2666.
54. Borras T., Tamm E.R., Zigler J.S. Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Invest Ophthalmol Vis Sci 1996, 37:1282-1293.
55. Xiao X., Li J., McCown T.J., Samulski R.J. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 1997, 144:113-124.
56. Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996, 2:545-550.
57. Wang B., Li J., Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000, 97:13714-13719.
58. Bueler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem 1999, 380:613-622.
59. Nakai H., Yant S.R., Storm T.A., Fuess S., Meuse L., Kay M.A. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001, 75:6969-6976.
60. Penaud-Budloo M., Le Guiner C., Nowrouzi A., Toromanoff A., Chérel Y., Chenuaud P., et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 2008, 82:7875-7885.
61. Li Q., Miller R., Han P.Y., Pang J., Dinculescu A., Chiodo V., et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008, 14:1760-1769.
62. Wu W.C., Lai C.C., Chen S.L., Sun M.H., Xiao X., Chen T.L., et al. GDNF gene therapy attenuates retinal ischemic injuries in rats. Mol Vis 2004, 10:93-102.
63. Mo J.S., Matsukawa A., Ohkawara S., Yoshinaga M. Involvement of TNF-α, IL-1beta and IL-1 receptor antagonist in LPS induced rabbit uveitis. Exp Eye Res 1998, 66:547-557.
64. Yoshida M., Yoshimura N., Hangai M., Tanihara H., Honda Y. Interleukin-1α, interleukin-1beta, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1994, 35:1107-1113.
65. El-Shabrawi Y.G., Christen W.G., Foster S.C. Correlation of metalloproteinase-2 and -9 with proinflammatory cytokines interleukin-1beta, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res 2000, 20:211-214.
66. Agarwal R.K., Kang Y., Zambidis E., Scott D.W., Chan C.C., Caspi R.R. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 2000, 106:245-252.
67. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature (London) 1953, 172:603-606.
68. Borel Y., Lewis R.M., Stollar B.D. Prevention of murine lupus nephritis by carrier-dependent induction of immunologic tolerance to denatured DNA. Science 1973, 182:76-78.
69. Borel Y. Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev 1980, 50:71-104.
70. Choi B., Hwang Y., Kwon H.J., Lee E.S., Park K.S., Bang D., et al. Tumor necrosis factor-α small interfering RNA decreases herpes simplex virus induced inflammation in a mouse model. J Dermatol Sci 2008, 52:87-97.
71. Hou Y., Xing L., Fu S., Zhang X., Liu J., Liu H., et al. Down regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats. Graefes Arch Clin Exp Ophthalmol 2009, 247:755-765.